Bobby Gaspar - Oct 4, 2022 Form 4 Insider Report for Orchard Therapeutics plc (ORTX)

Role
Chief Executive Officer, Director
Signature
/s/ Frank E. Thomas, as Attorney-in-Fact
Stock symbol
ORTX
Transactions as of
Oct 4, 2022
Transactions value $
$0
Form type
4
Date filed
10/6/2022, 06:11 PM
Previous filing
Jun 3, 2022
Next filing
Mar 3, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORTX Stock Option (Right to Buy) Disposed to Issuer $0 -50K -100% $0.00* 0 Oct 4, 2022 Ordinary Shares 50K $12.54 Direct F1, F2, F3
transaction ORTX Stock Option (Right to Buy) Award $0 +50K $0.00 50K Oct 4, 2022 Ordinary Shares 50K $0.58 Direct F1, F2, F3
transaction ORTX Stock Option (Right to Buy) Disposed to Issuer $0 -200K -100% $0.00* 0 Oct 4, 2022 Ordinary Shares 200K $13.58 Direct F1, F3, F4
transaction ORTX Stock Option (Right to Buy) Award $0 +200K $0.00 200K Oct 4, 2022 Ordinary Shares 200K $0.58 Direct F1, F3, F4
transaction ORTX Stock Option (Right to Buy) Disposed to Issuer $0 -300K -100% $0.00* 0 Oct 4, 2022 Ordinary Shares 300K $7.05 Direct F1, F3, F5
transaction ORTX Stock Option (Right to Buy) Award $0 +300K $0.00 300K Oct 4, 2022 Ordinary Shares 300K $0.58 Direct F1, F3, F5
transaction ORTX Stock Option (Right to Buy) Disposed to Issuer $0 -850K -100% $0.00* 0 Oct 4, 2022 Ordinary Shares 850K $5.98 Direct F1, F3, F6
transaction ORTX Stock Option (Right to Buy) Award $0 +850K $0.00 850K Oct 4, 2022 Ordinary Shares 850K $0.58 Direct F1, F3, F6
transaction ORTX Stock Option (Right to Buy) Disposed to Issuer $0 -55K -100% $0.00* 0 Oct 4, 2022 Ordinary Shares 55K $5.98 Direct F1, F3, F7
transaction ORTX Stock Option (Right to Buy) Award $0 +55K $0.00 55K Oct 4, 2022 Ordinary Shares 55K $0.58 Direct F1, F3, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
F2 The shares subject to this option vest in equal monthly installments over the four years after January 16, 2019.
F3 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F4 The shares subject to this option vest in equal monthly installments over the four years after January 2, 2020.
F5 The shares subject to this option vest in equal monthly installments over the four years after April 1, 2020.
F6 The shares subject to this option vest in equal monthly installments over the four years after February 1, 2021.
F7 The shares subject to this option are fully vested as of the date hereof.